Crescent Biopharma (CBIO) Stock: Buy, Sell, or Hold?
CBIO - Crescent Biopharma, Inc. Common Stock
$19.41
-0.05 (-0.26%)
▼
5d:
-4.85%
30d:
+18.14%
90d:
+5.83%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CBIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CBIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CBIO is currently trading at $19.41, which is considered extended relative to its 30-day fair value range of $16.30 to $19.11.
Technical Outlook: Technically, CBIO is in a downtrend. Immediate support is located at $16.14, while resistance sits at $22.33.
Market Sentiment: CBIO scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.60 (+57.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CBIO is in a downtrend. Immediate support is located at $16.14, while resistance sits at $22.33.
Market Sentiment: CBIO scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.60 (+57.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.30 -
$19.11
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.7% below Wall St target ($30.60)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.30 -
$19.11
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.14
Resistance Level
$22.33
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.38
Wall Street Target
$30.60
(+57.7%)
Share & Embed Analysis
Last updated: September 12, 2026 8:59 AM ET
Data refreshes hourly during market hours. Next update: 9:59 AM
Data refreshes hourly during market hours. Next update: 9:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |